Drug firm Glenmark Pharmaceuticals on Monday said it has cut price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19, by 27 per cent to ₹75 per tablet.
Glenmark Pharmaceuticals had launched FabiFlu last month at a price of ₹103 per tablet.
In a regulatory filing Glenmark announced a price reduction of 27 per cent for FabiFlu. The new maximum retail price (MRP) is ₹75 per tab, it said.
"The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark's facilities in India, the benefits of which are being passed on to patients in the country," the filing said.
"Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country," Glenmark Pharmaceuticals Senior Vice President and Head – India business Alok Malik said.
Further, the company has commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1,000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study, the filing added.
"We expect this post marketing surveillance study to shed more light on the drug's clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu," Malik added.
On June 20, Glenmark announced that it received manufacturing and marketing approval from India's drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.
Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India. The trial results will be available shortly, the company said.
Glenmark is also conducting another phase 3 clinical trial to evaluate the efficacy of two antivirals drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalised adult COVID-19 patients in India.
Shares of Glenmark Pharma were trading 1.34 per cent lower at ₹421.00 apiece on BSE. PTI SVK DRR DRR
May 19, 2020 0 2042
May 1, 2020 0 2488
Apr 20, 2020 0 1871
Jun 18, 2020 1 1465
Jan 23, 2020 0 1929
Feb 24, 2020 0 1000
Jun 5, 2021 0 18
In the first phase, the yatra will be opened for residents of Chamoli, Rudraprayag...
Nov 22, 2019 0 2014
From scenic byways to wine country destinations to historic honky-tonks, these Californian...
Mar 15, 2021 0 92
Before you invest your hard-earned money in any of the available investment options,...
Nov 22, 2019 0 1884
Two of the petrol offerings in the car include a 1.2-litre Kappa dual VTVT engine...
Aug 21, 2019 0 838
Many Marvel fans are having trouble imagining Spider-Man films without that MCU...
Dec 16, 2020 0 6332
To provide more funds at the disposal of the taxpayers in these difficult times,...
Jun 10, 2021 0 1020
If you are also planning to link your Aadhaar Card with your Driving license, then...
Mar 18, 2021 0 180
The lump-sum amount deposited is repaid over a period in equated monthly instalment...
Sep 2, 2019 0 2221
The Kia Seltos arrived with a price tag of Rs 9.69 lakh undercutting its major rivals...
Aug 22, 2019 0 951
The beta version of PUBG Mobile in China has got a new mode which lets you fly helicopters,...
Jun 10, 2021 0 1020
Jun 10, 2021 0 2131
Jun 10, 2021 0 61
Jun 10, 2021 0 377
Jun 5, 2021 0 43249
Jun 5, 2021 0 17985
Nov 4, 2020 5 2538
Jun 10, 2021 0 2139
May 3, 2021 0 1967